Holen Sie sich die Stockscreener-App
55.00
4.24%
-2.42
Scholar Rock Holding Corp Aktie (SRRK) Neueste Nachrichten
Scholar Rock at cantor global healthcare conference: approval clock nears By Investing.com - Investing.com India
SRRK Reiterates by HC Wainwright & Co. -- Price Target Maintained at $65 - GuruFocus
Scholar Rock's (SRRK) Buy Rating Reaffirmed at HC Wainwright - marketbeat.com
Legal & General Group Plc Invests $3.36 Million in Scholar Rock Holding Corporation $SRRK - marketbeat.com
Scholar Rock (SRRK) Gains FDA Fast Track for Apitegromab Amid Hi - GuruFocus
122,223 Shares in Scholar Rock Holding Corporation $SRRK Acquired by The Manufacturers Life Insurance Company - marketbeat.com
Beaconlight Capital LLC Makes New Investment in Scholar Rock Holding Corporation $SRRK - MarketBeat
Scholar Rock Holding (SRRK) Stock Dropped, So What Is Behind The Latest Attention? - simplywall.st
Bank of New York Mellon Corp Acquires New Shares in Scholar Rock Holding Corporation $SRRK - marketbeat.com
104,346 Shares in Scholar Rock Holding Corporation $SRRK Acquired by Man Group plc - MarketBeat
Algert Global LLC Grows Stock Holdings in Scholar Rock Holding Corporation $SRRK - marketbeat.com
96,285 Shares in Scholar Rock Holding Corporation $SRRK Acquired by Artia Global Partners LP - marketbeat.com
Scholar Rock (NASDAQ:SRRK) Shares Up 5.8%Still a Buy? - marketbeat.com
Nicholas Investment Partners LP Purchases New Position in Scholar Rock Holding Corporation $SRRK - MarketBeat
Scholar Rock Holding Corp stock hits 52-week high at 58.52 USD - Investing.com Canada
303,268 Shares in Scholar Rock Holding Corporation $SRRK Bought by Deutsche Bank AG - marketbeat.com
Scholar Rock (SRRK) Streamlines Apitegromab Filings After Catalent Shift Is Regulatory Strategy De-Risking The Story? - Yahoo Finance
SRRK Stock Gains After Company Drops Troubled Novo Nordisk-Owned Plant From FDA Filing - Stocktwits
Scholar Rock withdraws Europe filing for muscle weakness drug, plans resubmission - Reuters
Scholar Rock (NASDAQ:SRRK): Healthcare Milestone Draws Focus - Kalkine Media
Scholar Rock advances apitegromab FDA review - grafa.com
Scholar Rock removes Catalent facility from SMA drug application By Investing.com - Investing.com Canada
Scholar Rock is prepared to launch its SMA drug if FDA approves by Sept. 30 - Stock Titan
Eagle Health Investments LP Invests $30.54 Million in Scholar Rock Holding Corporation $SRRK - MarketBeat
Scholar Rock Holding Corporation (NASDAQ:SRRK) Receives Consensus Rating of "Buy" from Brokerages - marketbeat.com
Scholar Rock Holding (SRRK) After Apitegromab Progress Is The Stock Already Fully Valued - Sahm
Scholar Rock Eyes Sept. 30 FDA Decision for SMA Drug Apitegromab - MarketBeat
How Investors Are Reacting To Scholar Rock (SRRK) Dual Fill-Finish Readiness Amid Ongoing FDA Review - simplywall.st
Is Scholar Rock Holding Corporation (SRRK) Better Positioned than Novo Nordisk A/S (NVO) After Recent Setbacks? - Yahoo Finance
Redmile Group (SRRK) updates Scholar Rock stake to 3.6% of common stock - Stock Titan
12 New Hires Receive 51,947 Scholar Rock Equity Awards - Stock Titan
Scholar Rock Reports New Employee Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - Yahoo Finance
SRRK Stock Surges To Near Five-Year Highs – Here’s Why Analysts Are Bullish About Its Latest FDA Filing - Stocktwits
Scholar Rock (SRRK) Stock Looks Priced At A Premium Today - simplywall.st
SRRK Maintains by JP Morgan -- Price Target Raised to $63.00 - GuruFocus
Scholar Rock (NASDAQ:SRRK) Stock Price Expected to Rise, JPMorgan Chase & Co. Analyst Says - MarketBeat
Invus reports 8.0% stake in Scholar Rock (SRRK) through 9.6M shares - Stock Titan
SRRK Stock Prediction: Huge SMA Drug Launch Breakthrough? (2026 Alert) The Rock (yAPbDwyblt) - Mshale
Scholar Rock at canaccord growth conference: approval path narrows By Investing.com - Investing.com Canada
Scholar Rock at canaccord growth conference: approval path narrows - Investing.com India
Scholar Rock Overcomes Manufacturing Hurdle to Keep Lead Drug FDA Review on Schedule - Sahm
Q3 EPS Estimates for Scholar Rock Cut by HC Wainwright - MarketBeat
Scholar Rock: Apitegromab's Approval Is Key, Here's My Take Moscow Victory Day Parade (Ok0Q1xN954) - Mshale
Scholar Rock Holding Corporation (SRRK) Stock Analysis: A Potential 15.51% Upside in the Biotech Arena - DirectorsTalk Interviews
Bank of America Corp DE Buys 286,126 Shares of Scholar Rock Holding Corporation $SRRK - MarketBeat
SRRK Reiterated by Wedbush -- Maintains Price Target at $58.00 - GuruFocus
Scholar Rock's (SRRK) Outperform Rating Reiterated at Wedbush - MarketBeat
H.C. Wainwright reiterates Scholar Rock stock rating at buy By Investing.com - Investing.com South Africa
H.C. Wainwright reiterates Scholar Rock stock rating at buy - Investing.com
SRRK Reiterated by HC Wainwright & Co. -- Price Target Maintained at $65 - GuruFocus
Scholar Rock Holding Corp (SRRK) Earnings Forecast: Future EPS & Revenue Growth Estimates - TradingKey
SRRK Maintained at Buy by Citigroup -- Price Target Raised to $6 - GuruFocus
Scholar Rock drops Novo Nordisk facility from marketing application for muscle weakness drug - marketscreener.com
Vials for an SMA treatment candidate await packaging as FDA review shifts - Stock Titan
Scholar Rock Q2 Earnings Call Highlights - finance.yahoo.com
SRRK SWOT Analysis: Financial Challenges and Growth Potential Re - GuruFocus
0.29%
4.16%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):